Abstract:Objective. Polycystic ovary syndrome (PCOS) is one of the prevalent gynecological endocrine disorders encountered in clinical practice. Women diagnosed with PCOS demonstrate increased ovarian responsiveness, rendering them more prone to ovarian hyperstimulation syndrome (OHSS) during controlled ovarian stimulation (COS) procedures. The current study aimed at investigating whether CCL25/CCR9 plays a role in the pathological process of high ovarian response (HOR) during COS procedures. Design. Single‐center retrospective cohort study. Patients. A total of 200 PCOS patients who received a fixed regimen of gonadotropin‐releasing hormone (GnRH) antagonist were enrolled in this study. The cohort comprised 118 patients exhibiting HOR and 82 patients demonstrating a normal ovarian response (NOR). Results. The age and body mass index (BMI) variances across the two groups did not differ significantly. Similarly, the two groups observed no statistically significant differences in the baseline levels of luteinizing hormone (LH), progesterone (P), estradiol (E 2 ), basal prolactin (PRL), and testosterone (T). Compared to the NOR group, HOR patients exhibit markedly elevated levels of anti‐Müllerian hormone (AMH), antral follicle count (AFC), basal follicle‐stimulating hormone (FSH), and HOMA‐IR (all p < 0.05). Conversely, no statistically significant differences were observed between the two groups with respect to COS parameters, encompassing initial gonadotropin (Gn) dose, stimulation duration, and total Gn dose. During COS, the number of oocytes with diameter ≥14 mm, the levels of E 2 on the HCG day, and the number of retrieved oocytes were significantly higher in the HOR group than in the NOR group (all p < 0.001). Additionally, the levels of CCL25/CCR9, matrix metalloproteinases (MMPs), tissue inhibitor of metalloproteinases (TIMPs), TNF‐α, and IL‐6 were significantly higher in the FF of the HOR group than in the NOR group (all p < 0. 001), while the variance in IL‐1β levels between the two cohorts did not reach statistical significance. The relevance analysis results indicated that the levels of CCL25/CCR9 in the FF of the HOR group are positively correlated with the number of retrieved oocytes and oocytes with diameters ≥14 mm during COS, AMH levels, and AFC. Concurrently, the CCL25 levels in the FF of the HOR group were positively correlated with HOMA‐IR. Multivariable linear regression analysis revealed that the elevated AFC and HOMA‐IR independently increase the CCL25 levels. Conclusion. The CCL25/CCR9 levels in FF are positively correlated with the clinical indicators of HOR, suggesting that CCL25/CCR9 may play a role in the pathogenesis of HOR in patients with PCOS.

Abnormal luteinizing hormone response patterns to synthetic gonadotrophin releasing hormone in patients with polycystic ovarian syndrome

Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH

Gonadotropin levels in women with polycystic ovary syndrome: their relationship to body weight and insulin levels

Premature response to luteinizing hormone of granulosa cells from women with polycystic ovary syndrome

Short-term endocrine response to gonadotropin-releasing hormone agonist initiated in the early follicular, midluteal, or late luteal phase in normally cycling women

Poor Ovarian Response To Gonadotropin Stimulation Is Associated With Low Expression Of Follicle-Stimulating Hormone Receptor In Granulosa Cells

Relationship between CCL25/CCR9 Levels in Follicular Fluid and High Ovarian Response in Patients with Polycystic Ovary Syndrome

Effect of growth hormone on the outcome of ovulation induction in patients with polycystic ovary syndrome]

Response of IGF and IL-6 to ovarian stimulation in PCOS and normal women

Effects of letrozole alone or letrozole in combination with low-dose intramuscular injection of human menopausal gonadotropin on ovulation and pregnancy of 150 patients with polycystic ovary syndrome

Elevated basal luteinizing hormone does not impair the outcome of human menopausal gonadotropin and medroxyprogesterone acetate treatment cycles

The Effectiveness of Gonadotrophin Releasing Hormone Agonist on Infertile Patients with Ovulation Disorder and Poor Response

Microscopic characterization of follicular structures in letrozole-induced polycystic ovarian syndrome in the rat

GnRHa combined with low dose hCG trigger in in vitro fertilization treatment of polycystic ovary syndrome high responders

[Effect of Luteinizing Hormone Vs Follicular Stimulating Hormone Ratio on Anti-Müllerian Hormone Secretion and Folliculogenesis in Patients with Polycystic Ovarian Syndrome].

Progesterone levels on the hCG day and outcomes in vitro fertilization in women with polycystic ovary syndrome

Acute progesterone feedback on gonadotropin secretion is not demonstrably altered in estradiol-pretreated women with polycystic ovary syndrome

Metabolic landscape and pathogenic insights: a comprehensive analysis of high ovarian response in infertile women undergoing in vitro fertilization

Comparison of Hormonal and Metabolic Characteristics and Ovary Response to Induced Ovulation in Amenorrheic and Oligomenorrheic Women with PCOS

Ovarian suppression reduces clinical and endocrine expression of late-onset congenital adrenal hyperplasia due to 21-hydroxylase deficiency

Role of Luteinizing Hormone Elevation in Outcomes of Ovulation Induction with Letrozole for Polycystic Ovary Syndrome